AR105761A1 - Neurotoxinas clostridiales recombinantes con una mayor duración del efecto - Google Patents

Neurotoxinas clostridiales recombinantes con una mayor duración del efecto

Info

Publication number
AR105761A1
AR105761A1 ARP160101721A ARP160101721A AR105761A1 AR 105761 A1 AR105761 A1 AR 105761A1 AR P160101721 A ARP160101721 A AR P160101721A AR P160101721 A ARP160101721 A AR P160101721A AR 105761 A1 AR105761 A1 AR 105761A1
Authority
AR
Argentina
Prior art keywords
recombinant
effect
clostridial neurotoxins
nucleic acid
acid sequence
Prior art date
Application number
ARP160101721A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR105761A1 publication Critical patent/AR105761A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a neurotoxinas clostridiales recombinantes que exhiben aumento de la duración del efecto y a métodos para la fabricación de tales neurotoxinas clostridiales recombinantes. Estas neurotoxinas clostridiales recombinantes comprenden un dominio de espiral al azar, y los métodos comprenden las etapas de insertar una secuencia de ácido nucleico que codifica para un dominio de espiral al azar en una secuencia de ácido nucleico que codifica para una neurotoxina clostridial parental y la expresión de la secuencia de ácido nucleico recombinante que comprende la secuencia que codifica el dominio de espiral al azar en una célula huésped. Se refiere además a neurotoxinas clostridiales precursoras de una sola cadena recombinantes utilizadas en tales métodos, las secuencias de ácidos nucleicos que codifican tales neurotoxinas clostridiales precursoras de cadena simple recombinantes, y composiciones farmacéuticas que comprenden la neurotoxina clostridial recombinante con un aumento de la duración del efecto.
ARP160101721A 2015-06-11 2016-06-09 Neurotoxinas clostridiales recombinantes con una mayor duración del efecto AR105761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15001733 2015-06-11

Publications (1)

Publication Number Publication Date
AR105761A1 true AR105761A1 (es) 2017-11-08

Family

ID=53404318

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101721A AR105761A1 (es) 2015-06-11 2016-06-09 Neurotoxinas clostridiales recombinantes con una mayor duración del efecto

Country Status (6)

Country Link
US (2) US10603353B2 (es)
EP (1) EP3307302B1 (es)
AR (1) AR105761A1 (es)
ES (1) ES2784911T3 (es)
TW (1) TW201718627A (es)
WO (1) WO2016198163A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
BR112018014445A2 (pt) 2016-03-02 2018-12-11 Merz Pharma Gmbh & Co Kgaa composição que compreende toxina botulínica
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) * 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
WO2019101308A1 (en) * 2017-11-22 2019-05-31 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695623B2 (en) 1994-05-31 1998-08-20 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
WO1996039166A1 (en) 1995-06-06 1996-12-12 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions of botulinum toxin
US6214602B1 (en) 1998-08-28 2001-04-10 Promega Corporation Host cells for expression of clostridial toxins and proteins
WO2001014570A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
CA2428270C (en) * 2000-11-06 2013-07-02 Leonard A. Smith Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
KR101300929B1 (ko) * 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
AU2005271372B2 (en) 2004-08-04 2012-05-03 Allergan, Inc. Optimizing expression of active botulinum toxin type A
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
KR101701080B1 (ko) * 2007-06-21 2017-01-31 엑스엘-프로테인 게엠베하 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
CN102131823A (zh) * 2008-08-29 2011-07-20 德国麦氏大药厂 具有改变的持久性的梭状芽孢杆菌神经毒素
CN102471765B9 (zh) * 2009-07-02 2016-07-27 莫茨制药有限及两合公司 显示出缩短的生物学活性的神经毒素
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
JP2014534265A (ja) * 2011-11-28 2014-12-18 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド インスリンアミノ酸配列を含む治療薬
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
EP3372239B1 (en) * 2012-05-30 2020-11-11 President and Fellows of Harvard College Engineered botulinum neurotoxin
CA2881898A1 (en) * 2012-08-20 2014-02-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of recombinant proteins harbouring an n-terminal lysine
EP2925362A4 (en) * 2012-11-28 2016-07-20 Cnj Holdings Inc ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
EP2928912A1 (en) * 2012-12-05 2015-10-14 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with enhanced membrane localization
CA2899961C (en) * 2013-02-14 2022-08-09 Cornell University Methods to protect against and treat multiple sclerosis
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
ES2704237T3 (es) * 2014-03-05 2019-03-15 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con un aumento de la duración del efecto
RU2670135C2 (ru) * 2014-05-29 2018-10-18 Проуселл Терапьютикс Инк. Новый проникающий в клетки пептид, его конъюгат с ботулотоксином и их применение
WO2016073562A1 (en) * 2014-11-04 2016-05-12 Synthetic Biologics, Inc. Methods and compositions for inhibiting clostridium difficile
EP3822286A1 (en) * 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
US11753633B2 (en) * 2015-08-27 2023-09-12 President And Fellows Of Harvard College Compositions and methods for treatment of pain
WO2017125487A1 (en) * 2016-01-20 2017-07-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect
KR20190025906A (ko) * 2016-06-08 2019-03-12 칠드런'즈 메디컬 센터 코포레이션 조작된 보툴리눔 신경독소
US11117935B2 (en) * 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3290437A1 (en) * 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312193A1 (en) * 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
EP3335719A1 (en) * 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
EP3642222A1 (en) * 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) * 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
WO2019015673A1 (en) * 2017-07-21 2019-01-24 Shanghaitech University TOPICAL COMPOSITIONS AND USES THEREOF
WO2019081022A1 (en) * 2017-10-26 2019-05-02 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION
WO2019101308A1 (en) * 2017-11-22 2019-05-31 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect

Also Published As

Publication number Publication date
TW201718627A (zh) 2017-06-01
US11357821B2 (en) 2022-06-14
ES2784911T3 (es) 2020-10-02
EP3307302A1 (en) 2018-04-18
WO2016198163A1 (en) 2016-12-15
US10603353B2 (en) 2020-03-31
US20180169182A1 (en) 2018-06-21
EP3307302B1 (en) 2020-03-18
US20200129587A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
AR105761A1 (es) Neurotoxinas clostridiales recombinantes con una mayor duración del efecto
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CL2016003041A1 (es) Ácidos ribonucleicos bicatenarios aislados, composiciones farmacéuticas que los comprenden y método para inhibir la expresión del gen alas1 basado en la administración de dicha composición. divisional de solicitud 2725-2014.
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
AR105470A1 (es) Métodos para inducir una respuesta inmune
DOP2017000094A (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
CL2018000899A1 (es) Compuestos y métodos para modular expresión de angiotensinógeno.
CO2017000510A2 (es) Constructos de car
AR091320A1 (es) Composiciones solubles en agua que incorporan enzimas y metodos para fabricarlas
CO7121328A2 (es) Composiciones de ester de ácido graso omega -3
PE20151998A1 (es) Moleculas fc biespecificas
CR20150603A (es) Metaloproteinasa de la matriz y usos del mismo
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
PE20171042A1 (es) Inhibidores del bromodominio
CO2018008847A2 (es) Formulaciones líquidas inhibidoras de ureasa
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
AR110677A1 (es) Anticuerpos anti-c1s y métodos para usarlos
BR112016011638A2 (pt) composição dispersável em água, artigo moldado, e, método para formar uma peça moldada por injeção
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo

Legal Events

Date Code Title Description
FB Suspension of granting procedure